Serial direct sodium removal in patients with heart failure and diuretic resistance

Veena S. Rao, Juan B. Ivey-Miranda,Zachary L. Cox,Julieta Moreno-Villagomez, Daniela Ramos-Mastache, Daniel Neville, Natasha Balkcom,Jennifer L. Asher,Lavanya Bellumkonda, Tamar Bigvava,Tamaz Shaburishvili,Jozef Bartunek,F. Perry Wilson, Fredrick Finkelstein,Christopher Maulion, Jeffrey M. Turner, Jeffrey M. Testani

EUROPEAN JOURNAL OF HEART FAILURE(2024)

引用 0|浏览6
暂无评分
摘要
Aims Loop diuretics may exacerbate cardiorenal syndrome (CRS) in heart failure (HF). Direct sodium removal (DSR) using the peritoneal membrane, in conjunction with complete diuretic withdrawal, may improve CRS and diuretic resistance. Methods and results Patients with HF requiring high-dose loop diuretics were enrolled in two prospective, single-arm studies: RED DESERT (n = 8 euvolaemic patients), and SAHARA (n = 10 hypervolaemic patients). Loop diuretics were withdrawn, and serial DSR was utilized to achieve and maintain euvolaemia. At baseline, participants required a median 240 mg (interquartile range [IQR] 200-400) oral furosemide equivalents/day, which was withdrawn in all participants during DSR (median time of DSR 4 weeks [IQR 4-6]). Diuretic response (queried by formal 40 mg intravenous furosemide challenge and 6 h urine sodium quantification) increased substantially from baseline (81 +/- 37 mmol) to end of DSR (223 +/- 71 mmol, p < 0.001). Median time to re-initiate diuretics was 87 days, and the median re-initiation dose was 8% (IQR 6-10%) of baseline. At 1 year, diuretic dose remained substantially below baseline (30 [IQR 7.5-40] mg furosemide equivalents/day). Multiple dimensions of kidney function such as filtration, uraemic toxin excretion, kidney injury, and electrolyte handling improved (p < 0.05 for all). HF-related biomarkers including N-terminal pro-B-type natriuretic peptide, carbohydrate antigen-125, soluble ST2, interleukin-6, and growth differentiation factor-15 (p < 0.003 for all) also improved. Conclusions In patients with HF and diuretic resistance, serial DSR therapy with loop diuretic withdrawal was feasible and associated with substantial and persistent improvement in diuretic resistance and several cardiorenal parameters. If replicated in randomized controlled studies, DSR may represent a novel therapy for diuretic resistance and CRS. Clinical Trial Registration: RED DESERT (NCT04116034), SAHARA (NCT04882358). [GRAPHICS] .
更多
查看译文
关键词
Cardiorenal syndrome,Diuretic,Heart failure,Sodium
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要